Rituximab and bendamustine in patients with CD20+ diffuse large B-cell lymphoma not eligible for cyclophosphamide, doxorubicin, vincristine and prednisone-like chemotherapy. [electronic resource]
Producer: 20130619Description: 2290-2 p. digitalISSN:- 1029-2403
- Adult
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Murine-Derived -- administration & dosage
- Antigens, CD20 -- analysis
- Antineoplastic Combined Chemotherapy Protocols -- therapeutic use
- Bendamustine Hydrochloride
- Cyclophosphamide -- therapeutic use
- Doxorubicin -- therapeutic use
- Female
- Humans
- Lymphoma, Large B-Cell, Diffuse -- drug therapy
- Male
- Middle Aged
- Nitrogen Mustard Compounds -- administration & dosage
- Prednisone -- therapeutic use
- Retrospective Studies
- Rituximab
- Vincristine -- therapeutic use
No physical items for this record
Publication Type: Letter
There are no comments on this title.
Log in to your account to post a comment.